Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

3321 results about "Specific antibody" patented technology

Antibodies recognize specific antigens by identifying certain areas on the surface of the antigen known as antigenic determinants. Once the specific antigenic determinant is recognized, the antibody will bind to the determinant. The antigen is tagged as an intruder and labeled for destruction by other immune cells.

Combination therapies for the treatment of cancer

Provided is combination therapies that involve a construct has a TIGIT-binding moiety and a PVRIG-binding moiety and a KRAS G12C inhibitor for treating cancer with KRAS G12C mutations. In some cases, the construct is a multispecific antibody or a bispecific antibody that recognizes PVRIG and TIGIT.
Owner:D3 BIO (WUXI) CO LTD

Therapeutic use of bispecific Anti-abeta / TFR antibodies

Herein is reported a bispecific antibody specifically binding to human Abeta protein and human transferrin receptor (bispecific anti-Abeta / TfR antibody) as well as the use of such bispecific antibodies as a medicament in the treatment of Alzheimer's Disease, including where the bispecific antibody is administered intravenously at a dose of 0.2 mg / kg to 7.2 mg / kg once every four weeks.
Owner:F HOFFMANN LA ROCHE & CO AG +1

Development, preparation and application of carbapenemase immunochromatography kit

The invention discloses development, preparation and application of a carbapenemase immunochromatography kit, and belongs to the technical field of biological medicines. According to comparison of amino acid sequences of five common carbapenemase variants of KPC, IMP, NDM, VIM and OXA48 types, the immunogen is prepared from conserved epitope sequences obtained respectively. A mouse is immunized, and a specific antibody pair which is strong in affinity and can be combined with multiple variants is obtained through multi-platform screening. On the basis, the carbapenemase quintuplet detection kit is developed by utilizing an immunochromatography method, has the advantages of high sensitivity, good specificity, capability of covering various drug-resistant variants, capability of detecting multiple targets at one time and rapidness and convenience in detection, and provides important help for clinical auxiliary diagnosis and medication guidance.
Owner:JIANGSU MEDOMICS MEDICAL TECHNOLOGY CO LTD

CTC cell detection method based on micro-fluidic chip

The invention discloses a CTC cell detection method based on a micro-fluidic chip, and belongs to the technical field of cell treatment. In order to solve the problems of high false positive and false negative rates, time consumption and low efficiency caused by difficulty in accurately distinguishing CTC from other cell types, the invention can efficiently and specifically capture CTC cells, reduce the possibility of false positive and false negative and improve the detection accuracy by constructing a specific capture chamber and filling specific antibodies and immunomagnetic beads. The multi-channel design allows a plurality of samples to be processed at the same time, the detection efficiency is improved, the micro-fluidic chip technology integrates a plurality of steps on one platform, automation and standardization of operation are achieved, personal errors are reduced, the stability and repeatability of detection are improved, the uniformity and stability of the detection process are ensured, and the detection efficiency is improved. The fluorescence imaging technology clearly displays CTC and obtains key parameters such as quantity, form and fluorescence intensity of CTC, thereby providing powerful support for cancer diagnosis and research.
Owner:TANSHENG TECHNOLOGY (ZHUJI) CO LTD +1

CD19 / CD38 multispecific antibodies

Provided herein are common light chain bispecific antibodies that bind CD38 and CD19. The common light chain bispecific antibodies comprise an anti-CD38 heavy chain variable region and anti CD19 heavy chain variable region that each have a negatively-charged amino acid at a terminal heavy chain variable region position. The common light chain bispecific antibodies comprise further comprise an anti-CD38 heavy chain constant region and anti-CD19 heavy chain constant region that each lack a C-terminal lysine residue. Further provided are nucleic acids encoding such common light chain bispecific antibodies and host cells comprising the nucleic acids. Also provided are methods of making such common light chain bispecific antibodies.
Owner:BIOGRAPH 55 INC

CysR structural domain specific antibody of PLA2R and application thereof

The invention discloses a specific antibody aiming at a CysR structural domain of PLA2R and application of the specific antibody, and belongs to the technical field of biological engineering. The invention provides a CysR structural domain antibody of PLA2R or an antigen binding fragment of the CysR structural domain antibody. The CysR structural domain antibody or the antigen binding fragment thereof provided by the invention can specifically recognize the corresponding PLA2R structural domain and has relatively high affinity. Besides, the invention provides a method for establishing a standard curve by using a CysR structural domain antibody of PLA2R as a standard substance, so that convenience is provided for clinical detection of concentrations of IgG with different anti-PLA2R epitopes.
Owner:NANJING VAZYME MEDICAL TECH CO LTD

Anti-PD-1 / CTLA-4 / VEGF ANTIBODIES AND USE THEREOF

Provided are anti-PD-1 antibodies and trispecific antibodies specifically binding to PD-1, CTLA-4 and VEGF, or antigen-binding fragments thereof, polynucleotides encoding the antibodies or antigen-binding fragments thereof, and methods of making and using the foregoing.
Owner:GENOR BIOPHARMA

Detection kit for epithelial-mesenchymal transition in EB (Epstein-Barr) virus infected thymoma and application of detection kit

The invention relates to a detection kit for epithelial-mesenchymal transition in EB virus infected thymoma and application, the detection kit comprises a quantum dot labeled antibody E-Cadherin and a quantum dot labeled antibody Vimentin, a quantum dot is coupled with a specific antibody, a thymoma paraffin section sample is dyed through the quantum dot and the specific antibody conjugate, and the EB virus infected thymoma is obtained. The conjugate can be specifically connected with an EMT related antigen expressed in the slice, so that the quantum dots can be used for qualitative or quantitative detection of the EMT-generated thymoma cells. The quantum dots are used for replacing fluorescent dye, direct marking of tissue slices can be achieved, local positioning of epithelial cells and mesenchymal tissues in the thymoma microenvironment is achieved, number detection and position detection can be achieved, and EMT condition evaluation is facilitated.
Owner:TIANJIN MEDICAL UNIV GENERAL HOSPITAL AIRPORT HOSPITAL

Specific antibody binding to coronavirus SARS-CoV-2 and SARS-CoV spike protein and application thereof

The invention discloses a specific antibody capable of combining with a coronavirus SARS-CoV-2 and an SARS-CoV spike protein (SARS-CoV spike protein), and an application of the specific antibody capable of combining with the coronavirus SARS-CoV-2 and the SARS-CoV spike protein. The sequences of the CDRs of the antibody disclosed by the invention are as shown in SEQ ID NO. 1 to SEQ ID NO. 6. The antibody provided by the invention comprises CDRs with a specific sequence, can be specifically combined with SARS-CoV-2 and SARS-CoV spike protein, and has a relatively strong binding reaction with spike protein of another highly pathogenic coronavirus MERS-CoV at the same time. The antibody provided by the invention is strong in targeting property and high in binding activity, and the antibody prepared by the preparation method provided by the invention is high in purity and can be prepared on a large scale. On the whole, the antibody disclosed by the invention can be used for developing and optimizing an SARS-CoV and SARS-CoV-2 infection detection method.
Owner:THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIV (GUANGZHOU RESPIRATORY CENT)

HMPV virus fusion protein F variant, mRNA vaccine and application thereof

The invention discloses an hMPV virus fusion protein F variant, an mRNA vaccine and application of the hMPV virus fusion protein F variant and the mRNA vaccine. The hMPV fusion protein F variant has amino acid residue difference on one or more sites relative to an hMPV fusion protein F with the login number of AGJ74096.1 in a GeneBank database, wherein the amino acid sequence of the hMPV fusion protein F variant is shown as SEQ ID NO: 1 or SEQ ID NO: 2. The mRNA vaccine designed based on the hMPV fusion protein F variant can induce a strong specific antibody reaction, the durability of the antibody in vivo is strong, the induced antibody can well neutralize an hMPV strain, the amplification of the hMPV in the lung is controlled, and the immune response of the hMPV in the lung is inhibited. Therefore, the specific antibody induced by the mRNA vaccine provides an effective basis for preventing hMPV virus infection related diseases and developing multi-combined vaccines.
Owner:NEXTRANSLATE BIOPHARMACEUTICAL (HANGZHOU) CO LTD

Combination of an ErbB-2 / ErbB-3 bispecific antibody with endocrine therapy for breast cancer

The invention relates to methods of treating of subject that has breast cancer or is at risk of having said cancer, comprising administering to the subject in need thereof a combination of a therapeutically effective amount of an ErbB-2 / ErbB-3 bispecific antibody and a therapeutically effective amount of an endocrine therapy drug, wherein the bispecific antibody has an antigen binding site that can bind an extra-cellular part of ErbB-2 and an antigen binding site that can bind an extra-cellular part of ErbB-3; and to means for said method.
Owner:MERUS NV

Anti-BCMA single-domain antibody, and preparation method therefor and use thereof

Provided are an anti-BCMA single-domain antibody, and a preparation method therefor and the use thereof. Specifically, provided is a single-domain antibody having an amino acid sequence of SEQ ID No. 1. The single-domain antibody has high affinity, can thoroughly specifically target BCMA-positive cells, and can be applied to the detection of BCMA expression in bone marrow cells of MM patients. The single-domain antibody can be prepared into a specific antibody drug clinically used for preventing and treating BCMA-target-related diseases (such as multiple myeloma, B-cell acute lymphoblastic leukemia, non-Hodgkin's lymphoma and Hodgkin's lymphoma); or a BCMA protein detection kit, etc. The single-domain antibody has a stable structure, a small molecular size, is easily recombinantly expressed and has a low production cost, can be used alone or as a drug delivery system to carry relevant drugs, and has very wide prospects and important significance in fields such as drug application and clinical diagnosis.
Owner:CARBIOGENE THERAPEUTICS CO LTD

Group of specific antibodies for detecting botulinum toxin A and application thereof

The invention provides a group of specific antibodies for detecting botulinum toxin A and application thereof, and belongs to the technical field of botulinum toxin detection. The invention provides a group of specific antibodies for detecting botulinum toxin A or antigen binding fragments thereof. The specific antibodies or the antigen binding fragments thereof comprise a rabbit monoclonal antibody 1F11 or an antigen binding fragment thereof and a rabbit monoclonal antibody 2A10 or an antigen binding fragment thereof. The time-resolved immunodetection kit prepared by the invention has good detection sensitivity, specificity, repeatability and sample matrix tolerance, the detection range is 0.02 ng / mL-10 ng / mL, the detection limit is 0.02 ng / mL, cross reaction with other serotype botulinum toxins (B, E and F) does not exist, and the time-resolved immunodetection kit is not influenced by sample matrixes such as ham sausages and thick broad-bean sauce. The detection system established by the invention has a good application prospect in detection of botulinum toxin type A.
Owner:ACADEMY OF MILITARY MEDICAL SCIENCES

Anti-CD3 antibody and use thereof

Provided are an anti-CD3 antibody or an antigen-binding fragment thereof, and a use thereof. The anti-CD3 antibody comprises: heavy chain variable region CDRs and light chain variable region CDRs, the heavy chain variable region CDRs having amino acid sequences as shown in any one of SEQ ID NOs: 1-3, 7-8 and 74-86 or a conservatively modified form thereof, and / or the light chain variable region CDRs having amino acid sequences as shown in any one of SEQ ID NOs: 4-6, 9 and 87-92 or a conservatively modified form thereof. The provided anti-CD3 antibody or antigen-binding fragment thereof can bind to human CD3 protein and reduce the production of pro-inflammatory cytokines, and a bispecific antibody constructed using same has high PBMC tumor-killing activity and weak promotion of the secretion of pro-inflammatory cytokines. A pharmaceutical composition prepared using the anti-CD3 antibody or the antigen-binding fragment thereof or a multi-specific antibody thereof has better safety, and has value for clinical applications and drug development.
Owner:HEFEI TG IMMUNOPHARMA CO LTD

Magnetic nano-enzyme probe and preparation method thereof, kit for detecting helicobacter pylori and application

The invention discloses a magnetic nano-enzyme probe and a preparation method thereof, a kit for detecting helicobacter pylori and application of the magnetic nano-enzyme probe, the core of the magnetic nano-enzyme probe is Fe3O4 nano-particles, magnetic enrichment capacity is provided, and interference of a complex matrix in a sample is eliminated; a layer of Pt nano-particles is electrostatically adsorbed through the cationic polymer to serve as a colorimetric interlayer, and a strong colorimetric signal is provided; au (at) Pt for modifying 5, 5 '-dithiobis (2-nitrobenzoic acid) is arranged on the surface layer and is used for providing strong catalytic signals and sites coupled with a large number of specific antibodies; meanwhile, the inner and outer layers of nano enzyme particles can synergistically enhance the catalytic action. The magnetic nano-enzyme probe disclosed by the invention has strong magnetic responsiveness, high colorimetric signal, strong catalytic activity and specific bacterium capturing capacity, realizes rapid enrichment and quantitative analysis of helicobacter pylori in a sample to be detected, eliminates matrix interference in practical application, and has high sensitivity and high specificity. The method has great potential in the aspects of high sensitivity and clinical monitoring of bacterial infection or pollution.
Owner:YOULIAN RUIKANG (SHANGHAI) GENE TECH CO LTD

LC-ms / ms quantitative determination method for Anti-novel coronavirus bispecific antibody drug

PCT designated stage expiredWO2024251258A1Component separationViral antibodySolid phase extraction
The present application relates to the technical field of antibody drug determination, and provides a liquid chromatography-tandem mass spectrometry (LC-MS / MS) quantitative determination method for an anti-novel coronavirus bispecific antibody drug. According to the method, characteristic peptide segments EAYGMDVWGQGTTVTVSSASTK and SLSLSPGGGSQVQLVQSGAEVK are used, and on the basis that the characteristic peptide segments comprise a stable isotope internal standard, the content of the anti-novel coronavirus bispecific antibody drug is accurately quantified on an LC-MS / MS platform by means of the process of protein precipitation, enzymolysis and solid-phase extraction. According to the present application, the method and the characteristic peptide segments are highly selective and specific for anti-novel coronavirus bispecific antibody YBSW015, without being interfered by a pre-existing anti-novel coronavirus antibody in a patient, have the characteristics of high efficiency and simplicity, and can be used for clinical monitoring of the anti-novel coronavirus bispecific antibody.
Owner:SUZHOU YABAO PHARMA R&D CO LTD

Method for detecting neutralizing antibody of double-antibody drug

ActiveCN120405153AChemiluminescene/bioluminescenceBiological testingVascular endothelial growth factor bindingAntiendomysial antibodies
The invention relates to anti-drug neutralizing antibody analysis. In particular, the present application relates to methods for detecting neutralizing antibodies against a vascular endothelial growth factor (VEGF) binding moiety and a programmed cell death ligand-1 (PD-L1) binding moiety in a biological sample from an individual administered a bispecific antibody drug comprising the VEGF binding moiety.
Owner:UNITED POWER PHARMA TECH CO LTD +1

Preparation and application of antibody capable of detecting various IMP variants

The invention discloses preparation and application of an antibody capable of detecting various IMP variants, and belongs to the field of biological medicine. According to the invention, a conserved epitope sequence of IMP enzyme is obtained according to comparison of amino acid sequences of all IMP variants, and an antibody of a spatial epitope is prepared through structural analysis of the epitope. After a mouse is immunized with IMP immunogen protein, hybridoma cells secreting antibodies are obtained through multi-technology platform screening, specific antibody pairs MK35G9 and MK56G2 which are high in affinity and can be combined with multiple IMP variants are obtained after sequencing, and corresponding CDR is obtained through analysis. According to the present invention, the IMP enzyme detection product development is performed based on the immunochromatography platform, such that advantages of high sensitivity, good specificity, covering of a variety of IMP variants, and rapid and convenient detection are provided, and important help is provided for clinical auxiliary diagnosis and medication guidance.
Owner:JIANGSU MEDOMICS MEDICAL TECHNOLOGY CO LTD

Specific antibody MR-34 targeting coronavirus MERS-CoV spike protein RBD

The invention discloses a specific antibody MR-34 for targeting a coronavirus MERS-CoV spike protein RBD (Radial Basis Disease). The sequences of the CDRs of the antibody disclosed by the invention are as shown in SEQ ID NO. 1 to SEQ ID NO. 6. The antibody provided by the invention contains CDRs with a specific sequence, and can be specifically combined with an MERS-CoV spike protein RBD structural domain. The antibody provided by the invention is strong in targeting property and high in binding activity, and the antibody prepared by the preparation method provided by the invention is high in purity and can be prepared on a large scale. On the whole, the antibody disclosed by the invention can be used for developing and optimizing an MERS-CoV infection detection method.
Owner:TECH CENT OF GUANGZHOU CUSTOMS +1

Pseudorabies virus gD recombinant protein, subunit vaccine as well as preparation method and application of pseudorabies virus gD recombinant protein and subunit vaccine

The invention relates to the technical field of biology, in particular to a pseudorabies virus gD recombinant protein, a subunit vaccine and a preparation method and application thereof.The gD recombinant protein sequentially comprises a signal peptide, a connecting peptide, the 21st-350th site of the gD protein, an enzyme cutting site and a His tag from the N end to the C end, the amino acid sequence of the 21st-350th site of the gD protein is shown as SEQ ID No.4, and the amino acid sequence of the 21st-350th site of the gD protein is shown as SEQ ID No.6. The pseudorabies virus gD recombinant protein has high immunogenicity, the prepared subunit vaccine can generate a specific antibody with neutralizing activity, mice do not die after challenge, the protection rate is 100%, the protection rate after challenge of pigs is 100%, pathological sections only show slight pathological changes, and the pseudorabies virus gD recombinant protein has wide application prospects.
Owner:HARBIN VETERINARY RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES (CHINA ANIMAL HEALTH & EPIDEMIOLOGY CENTER HARBIN BRANCH CENTER)

Human-derived anti-(poly-GA) dipeptide repeat (DPR) antibody

Provided are novel dipeptide repeat (DPR) specific antibodies (e.g., human-derived antibodies) as well as synthetic variants and biotechnological derivatives thereof, capable of binding C9orf72 poly-glycine-alanine DPRs, as well as methods and uses related thereto. The antibody of the present invention can be used in pharmaceutical and diagnostic compositions for DPR protein-targeted immunotherapy and diagnostics.
Owner:NEURIMMUNE AG +1

Bispecific antibody, drug conjugate thereof, and use thereof

Provided are a bispecific antibody, a drug conjugate thereof, and a use thereof. The bispecific antibody comprises an EGFR binding domain and an HER3 binding domain. The provided bispecific antibody and the drug conjugate thereof have excellent endocytosis effects, proliferation inhibition activity and tumor growth inhibition activity, as well as good in vivo safety.
Owner:DUALITY BIOLOGICS (SUZHOU) CO LTD

Method for in vivo generation of multispecific antibodies from monospecific antibodies

Herein is reported a method for the generation of multispecific antibodies directly on the cell-surface at the site of action by a half-antibody exchange reaction between two 2 / 3-IgGs or two 2 / 3-BiFabs destabilized in one half by asymmetric perturbing mutations fostering the generation of correctly assembled full length bi- or multispecific antibodies. The method is performed in the absence hinge region disulfide bonds in the starting 2 / 3-IgGs or 2 / 3-BiFabs.
Owner:F HOFFMANN LA ROCHE INC

Specific antibody for detecting human cardiac myosin binding protein C

ActiveCN119192364AImmunoglobulins against animals/humansDisease diagnosisMyosin binding protein C, cardiacCardiac Myosins
Owner:SHANGHAI XINMIAO BIOLOGICAL TECHNOLOGY CO LTD

Chicken infectious anemia virus subunit vaccine

The invention discloses a chicken infectious anemia virus subunit vaccine, and belongs to the technical field of animal disease vaccines. The invention provides a chicken infectious anemia virus subunit vaccine. Active ingredients of the chicken infectious anemia virus subunit vaccine are recombinant fusion protein of chicken infectious anemia virus VP1 protein B cell epitope and salmonella typhimurium flagellin. The B cell epitope of the chicken infectious anemia virus VP1 protein is obtained by connecting B cell antigen epitopes contained in the chicken infectious anemia virus VP1 protein through a connecting peptide. The salmonella typhimurium flagellin is obtained by deleting a hypervariable region of the salmonella typhimurium flagellin FliC. The fusion expression protein provided by the invention can induce generation of a specific IgG antibody after one-day-old SPF chicken, and after immunization for 28 days, immunized chicken flocks can resist challenge of chicken infectious anemia virus virulent strains, and 70% of challenge chicken flocks are protected without disease attack. The invention has great potential for clinical prevention and control of chicken infectious anemia virus infection.
Owner:JINYU YOUBANG BIOTECHNOLOGY (JIANGSU) CO LTD

Multi-specific antibody specifically binding to LIGHT and GM-CSFR alpha, and composition and application thereof

Relates to a multispecific antibody or antigen binding fragment specifically binding to LIGHT and GM-CSFR alpha, a composition containing the antibody or antigen binding fragment specifically binding to LIGHT and the antibody or antigen binding fragment specifically binding to GM-CSFR alpha, a pharmaceutical composition containing the multispecific antibody or composition, and a preparation method and application thereof. Including methods of using the same to prevent and treat inflammatory, respiratory or autoimmune diseases.
Owner:STAIDSON (BEIJING) BIOPHARMACEUTICALS CO LTD

Pharmaceutical composition of anti-CD3*CD20 bispecific antibody

The invention belongs to the field of biological medicine, and relates to a pharmaceutical composition of an anti-CD3 * CD20 bispecific antibody, in particular to a liquid preparation and a freeze-dried preparation of the bispecific antibody and medical application of the liquid preparation and the freeze-dried preparation. More specifically, the pharmaceutical composition contains an anti-CD3 * CD20 bispecific antibody, a buffer solution, a stabilizer and a surfactant, the pH value of the pharmaceutical composition is about 4.5-6.5, and the pharmaceutical composition has good stability.
Owner:SHANGHAI JUNSHI BIOSCIENCES CO LTD

Diagnostic antibody applicable to immunohistochemistry test of CD228

A specific antibody and an antigen binding fragment thereof against a CD228 protein, used for testing and treating multiple tumors, such as melanoma, mesothelioma, and colorectal cancer. An antibody binding fragment facilitates the diagnosis and treatment of cancer by specifically binding to CD228. The present invention further comprises antibody-drug conjugates (ADCs) in which drugs bind to antibodies by means of linkers, aiming to improve the treatment effect and reduce the impact on normal cells. Additionally, the present invention provides a nucleic acid encoding an antibody or an antigen binding fragment thereof, so as to produce a recombinant antibody or fragment. In addition, the present invention further provides a kit, used for laboratory research, clinical diagnosis and treatment effect monitoring, facilitating determination of whether tissues or cells express CD228, providing a new strategy for personalized and accurate treatment of cancer.
Owner:SHANDONG BIOANTY BIOLOGICAL TECH CO LTD

Pharmaceutical combination containing Anti-PD-1-Anti-vegfa bispecific antibody, and use thereof

The present invention relates to the field of tumor treatment and immunology biology. Provided are a pharmaceutical combination containing an anti-PD-1-anti-VEGFA bispecific antibody, and the use thereof. Specifically, the pharmaceutical combination comprises at least one bispecific antibody and at least one PARP inhibitor, wherein the bispecific antibody comprises a first protein functional region for targeting PD-1 and a second protein functional region for targeting VEGFA; and according to the EU numbering system, the heavy chain constant region of an immunoglobulin contained in the bispecific antibody is mutated at two sites, i.e. site 234 and site 235, and after mutation, the affinity constant of the bispecific antibody to FcγRI, FcγRIIa, FcγRIIIa and / or C1q is reduced compared with the affinity constant of the bispecific antibody thereto before mutation. The combined administration of the PARPi and the bispecific antibody has a significantly better therapeutic effect on tumors than the individual use of the PARPi or the bispecific antibody; and the present invention has good application prospects.
Owner:AKESO BIOPHARMA INC